Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Oncogene

• Publication date

  1997-08-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.onc.1201250PMID 9285690
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Involvement of Co-activator p300 in the Transcriptional Regulation of the HER-2/neu Gene*

  1997cited by this paper
• Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene.

  1996cited by this paper
• Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms.

  1996cited by this paper
• Inhibition of intratracheal lung cancer development by systemic delivery of E1A.

  1996cited by this paper
• Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin.

  1996cited by this paper
• Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck.

  1995cited by this paper
• HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model.

  1995cited by this paper
• Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu.

  1995cited by this paper
• Adenovirus E1a-mediated tumor suppression by a c-erbB-2/neu-independent mechanism.

  1995cited by this paper
• Adenovirus E1A: transcription regulation and alteration of cell growth control.

  1995cited by this paper
• Cell cycle-dependent regulation of p185neu: a relationship between disruption of this regulation and transformation.

  1995cited by this paper
• Systemic Gene Therapy with p53 Reduces Growth and Metastases of a Malignant Human Breast Cancer in Nude Mice

  1995cited by this paper
• Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells.

  1995cited by this paper
• Regulation of her2/neu gene-expression (review).

  1995cited by this paper
• Transcriptional regulation of neu by RB and E1A in rat-1 cells.

  1994cited by this paper
• c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties.

  1994cited by this paper
• Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus.

  1994cited by this paper
• ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms.

  1994cited by this paper
• Greater enhancement of chemosensitivity by caffeine in high-p185neu-expressing human non-small-cell lung cancer cell lines.

  1994cited by this paper
• Synergism of taxol and gallium nitrate in human breast carcinoma cells: schedule dependency.

  1994cited by this paper
• p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

  1993cited by this paper
• Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.

  1993cited by this paper
• Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A.

  1993cited by this paper
• Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family.

  1993cited by this paper
• Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

  1992cited by this paper
• Widespread long-term gene transfer to mouse skeletal muscles and heart.

  1992cited by this paper
• Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products.

  1992cited by this paper
• Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.

  1992cited by this paper
• Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells.

  1991cited by this paper
• Mutations in p53 as potential molecular markers for human breast cancer.

  1991cited by this paper
• Repressed expression of the HER-2/c-erbB-2 proto-oncogene by the adenovirus E1a gene products.

  1991cited by this paper
• Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene

  1991cited by this paper
• Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.

  1991cited by this paper
• Effect of glucocorticoids on oncogene transformed NIH3T3 cells.

  1990cited by this paper
• Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products.

  1990cited by this paper
• Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.

  1989cited by this paper
• Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo

  1988cited by this paper
• Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene.

  1988cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines.

  1987cited by this paper
• Overexpression of the EGF receptor‐related proto‐oncogene erbB‐2 in human mammary tumor cell lines by different molecular mechanisms.

  1987cited by this paper
• Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene

  1987cited by this paper
• Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.

  1986cited by this paper
• Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor

  1986cited by this paper
• The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor.

  1985cited by this paper
• Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.

  1985cited by this paper
• Taxol stabilizes microtubules in mouse fibroblast cells.

  1980cited by this paper
• Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells.

  1979cited by this paper
• Enzyme and metabolic inhibitors

  1963cited by this paper

• SCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer

  2020cites this paper
• HER2 positivity may confer resistance to therapy with paclitaxel in breast cancer cell lines

  2018cites this paper
• Oncolytic virus and PD-1/PD-L1 blockade combination therapy

  2018cites this paper
• A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer

  2016cites this paper
• Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer.

  2016cites this paper
• A novel combined micellar system of lapatinib and Paclitaxel with enhanced antineoplastic effect against human epidermal growth factor receptor-2 positive breast tumor in vitro.

  2015cites this paper
• Polylactide-based paclitaxel-loaded nanoparticles fabricated by dispersion polymerization: characterization, evaluation in cancer cell lines, and preliminary biodistribution studies.

  2014cites this paper
• De-acetylation and degradation of HSPA5 is critical for E1A metastasis suppression in breast cancer cells

  2014cites this paper
• Abcc10 status affects mammary tumour growth, metastasis, and docetaxel treatment response

  2014cites this paper
• Efficient downregulation of ErbB2 induces TACC 1 upregulation in breast cancer cell lines

  2013cites this paper
• Efficient downregulation of ErbB-2 induces TACC1 upregulation in breast cancer cell lines.

  2013cites this paper
• αB-Crystallin promotes oncogenic transformation and inhibits caspase activation in cells primed for apoptosis by Rb inactivation

  2013cites this paper
• Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation

  2013cites this paper
• Liposome-Mediated Cancer Gene Therapy: Clinical Trials and their Lessons to Stem Cell Therapy

  2012cites this paper
• Advances in Liposome-Based Targeted Gene Therapy of Cancer

  2012cites this paper
• SV40 T/t-common polypeptide enhances the sensitivity of HER2-overexpressing human cancer cells to anticancer drugs cisplatin and doxorubicin.

  2012cites this paper
• Expression of the Adenovirus Early Gene 1A Transcription-Repression Domain Alone Downregulates HER2 and Results in the Death of Human Breast Cancer Cells Upregulated for the HER2 Proto-Oncogene.

  2011cites this paper
• FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization.

  2011cites this paper
• Anti-tumor Function of Double-promoter Regulated Adenovirus Carrying SEA Gene, in the Treatment of Bladder Cancer

  2011cites this paper
• Chemosensitization FOXO 3 a-Dependent Mechanism of E 1 A-Induced Updated

  2011cites this paper
• Silencing Kinase-Interacting Stathmin Gene Enhances Erlotinib Sensitivity by Inhibiting Ser10 p27 Phosphorylation in Epidermal Growth Factor Receptor–Expressing Breast Cancer

  2010cites this paper
• Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation

  2010cites this paper
• Design, synthesis, radiolabeling and in vitro and in vivo characterization of tumor-antigen- and antibody-derived peptides for the detection of breast cancer.

  2009cites this paper
• Identification of adenovirus E1A gene regions involved in chemosensitisation of prostate cancer cells

  2009cites this paper
• Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer

  2009cites this paper
• Cancer Therapy : Preclinical Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer

  2009cites this paper
• A novel hTERT promoter–driven E1A therapeutic for ovarian cancer

  2009cites this paper
• Breast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine.

  2009cites this paper
• Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma.

  2008cites this paper
• Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study

  2008cites this paper
• Trastuzumab: mechanisms of resistance and therapeutic opportunities.

  2008cites this paper
• The potential for treatment with dietary long-chain polyunsaturated n-3 fatty acids during chemotherapy.

  2008cites this paper
• EFEITO DO EGF NA REGULAÇÃO DOS TRANSCRITOS DE GENES IDENTIFICADOS COMO DIFERENCIALMENTE EXPRESSOS EM CÉLULAS DE MAMA EM CULTURA APRESENTANDO DIFERENTES NÍVEIS DE EXPRESSÃO DE ERBB2

  2008cites this paper
• HER2 and response to paclitaxel in node-positive breast cancer.

  2008cites this paper
• Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status

  2008cites this paper
• Therapeutic transfer of DNA encoding adenoviral E1A.

  2007cites this paper
• Trials and Tribulations in Developing Clinical Trials of Gene Therapy

  2007cites this paper
• Development of Therapeutic Genes for Breast Cancer Treatment

  2007cites this paper
• Downregulation of HER2/neu receptor by solamargine enhances anticancer drug-mediated cytotoxicity in breast cancer cells with high-expressing HER2/neu

  2007cites this paper
• Advances and perspectives in gene-based therapy for breast cancer

  2007cites this paper
• Novel approaches for chemosensitization of breast cancer cells: the E1A story.

  2007cites this paper
• Molecular mechanisms of erbB2-mediated breast cancer chemoresistance.

  2007cites this paper
• HER2 and response to paclitaxel in node-positive breast cancer.

  2007cites this paper
• Antitumor activity of an Ets protein, PEA3, in breast cancer cell lines MDA‐MB‐361DYT2 and BT474M1

  2006cites this paper
• Breast cancer gene therapy

  2006cites this paper
• Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15

  2006influential citation
• Biomarkers and multiple drug resistance in breast cancer.

  2006cites this paper
• Tumor Suppression and Sensitization to Taxol Induces Apoptosis of EIA in Breast Cancer Cells

  2005cites this paper
• Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells

  2005cites this paper
• Targeted gene therapy for ovarian cancer.

  2005cites this paper
• The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers.

  2005cites this paper
• Cancer-specific gene therapy.

  2005cites this paper
• Exogenous supplementation with omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells.

  2005cites this paper
• Gene Therapy for Patients With Head and Neck Cancer

  2005cites this paper
• Development of Oncolytic Adenoviruses

  2005cites this paper
• Exogenous supplementation with ω-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells

  2005cites this paper
• Exogenous supplementation with x-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells

  2005cites this paper
• Inhibition of Tumor-associated Fatty Acid Synthase Hyperactivity Induces Synergistic Chemosensitization of HER-2/neu-Overexpressing Human Breast Cancer Cells to Docetaxel (taxotere)

  2004cites this paper
• Involving Intraperitoneal Administration of E1A-Lipid Complex in Patients with Recurrent Epithelial Ovarian Cancer Overexpressing HER-2/neu Oncogene. Clin Cancer Res 2004;10: 2905–2907

  2004cites this paper
• E1A as a Tumor Suppressor Gene

  2004cites this paper
• Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer

  2004cites this paper
• 1 A as a Tumor Suppressor Gene Commentary

  2004cites this paper
• Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells.

  2003cites this paper
• EBNA1 may prolong G(2)/M phase and sensitize HER2/neu-overexpressing ovarian cancer cells to both topoisomerase II-targeting and paclitaxel drugs.

  2003cites this paper
• E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer.

  2003cites this paper
• Epigallocatechin-3-gallate Inhibits Activation of HER-2 / neu and Downstream Signaling Pathways in Human Head and Neck and Breast Carcinoma Cells 1

  2003cites this paper
• Gene therapy for ovarian cancer: progress and potential.

  2003cites this paper
• Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.

  2003cites this paper
• Regulation of the Activity of p38 Mitogen-Activated Protein Kinase by Akt in Cancer and Adenoviral Protein E1A-Mediated Sensitization to Apoptosis

  2003cites this paper
• Dysregulation of cellular signaling by HER2/neu in breast cancer.

  2003cites this paper
• Emerging new therapies for chemotherapy-resistant cancer using adenoviral vectors.

  2002cites this paper
• E1A Cancer Gene Therapy

  2002cites this paper
• CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells.

  2002cites this paper
• HER-2/Neu signaling and therapeutic approaches in breast cancer

  2002cites this paper
• E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor.

  2002cites this paper
• Cancer Gene Therapy: Past Achievements and Future Challenges

  2002cites this paper
• Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer.

  2002cites this paper
• Hyperthermia-regulated immunogene therapy

  2002cites this paper
• Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene.

  2002cites this paper
• Cancer therapy utilizing an adenoviral vector expressing only E1A

  2002cites this paper
• Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma.

  2002cites this paper
• CD44 Associates With EGFR and erbB2 in Metastasizing Mammary Carcinoma Cells

  2002cites this paper
• Head and neck cancer: gene therapy approaches.Part II: genes delivered

  2002cites this paper
• HER-2 in breast cancer--methods of detection, clinical significance and future prospects for treatment.

  2002cites this paper
• A multicenter phase II study of tgDCC‐E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma

  2002cites this paper
• The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (review).

  2002cites this paper
• Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial.

  2001cites this paper
• HER-2/neu oncogene expression in advanced breast cancer.

  2001cites this paper
• E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs.

  2001cites this paper
• E1A: Tumor suppressor or oncogene? Preclinical and clinical investigations ofE1A gene therapy

  2001cites this paper
• Drug Interactions of Paclitaxel and Docetaxel and their Relevance for the Design of Combination Therapy

  2001cites this paper
• RACK1 Interacts with E1A and Rescues E1A-induced Yeast Growth Inhibition and Mammalian Cell Apoptosis*

  2001cites this paper
• Mechanism of action of anti-HER2 monoclonal antibodies.

  2001cites this paper
• HER‐Kinase‐Directed Therapy of Prostate Cancer

  2001cites this paper
• Comparison of action of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cells.

  2000cites this paper
• Characterization of a Repressor Element and a Juxtaposed Tissue-restricted Activator Element Located on the Distal neu Gene Promoter*

  2000cites this paper
• E 1 A-mediated Paclitaxel Sensitization in HER-2 / neu-overexpressing Ovarian Cancer SKOV 3 . ip 1 through Apoptosis Involving the Caspase-3 Pathway 1

  2000cites this paper
• Adenovirus 5 early region 1A does not induce expression of the ewing sarcoma fusion product EWS-FLI1 in breast and ovarian cancer cell lines.

  2000cites this paper
• Role of erbB2 in breast cancer chemosensitivity.

  2000cites this paper
• Tumor heterogeneity: morphological, molecular and clinical implications.

  2000cites this paper